From Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (E.A.F., R.J.W., K.H.M., L.A.P., D.R.H., D.L.P.); and Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL (D.O.H., G.M.C.).
Circulation. 2016 Dec 6;134(23):1812-1821. doi: 10.1161/CIRCULATIONAHA.116.021949. Epub 2016 Oct 28.
The frequency of pulmonary vein stenosis (PVS) after ablation for atrial fibrillation has decreased, but it remains a highly morbid condition. Although treatment strategies including pulmonary vein dilation and stenting have been described, the long-term impacts of these interventions are unknown. We evaluated the presentation of severe PVS, and examined the risk for restenosis after intervention using either balloon angioplasty (BA) alone or BA with stenting.
This was a prospective, observational study of 124 patients with severe PVS evaluated between 2000 and 2014.
All 124 patients were identified as having severe PVS by computed tomography in 219 veins. One hundred two patients (82%) were symptomatic at diagnosis. The most common symptoms were dyspnea (67%), cough (45%), fatigue (45%), and decreased exercise tolerance (45%). Twenty-seven percent of patients experienced hemoptysis. Ninety-two veins were treated with BA, 86 were treated with stenting, and 41 veins were not treated. A 94% acute procedural success rate was observed and did not differ by initial management. Major procedural complications occurred in 4 of the 113 patients (3.5%) who underwent invasive assessment, and minor complications occurred in 15 patients (13.3%). Overall, 42% of veins developed restenosis including 27% of veins (n=23) treated with stenting and 57% of veins (n=52) treated with BA. The 3-year overall rate of restenosis was 37%, with 49% of BA-treated veins and 25% of stented veins developing restenosis (hazard ratio, 2.77; 95% confidence interval, 1.72-4.45; P<0.001). After adjustment for age, CHA2DS2-VASc score, hypertension, and the time period of the study, there was still a significant difference in the risk of restenosis for BA versus stenting (hazard ratio, 2.46; 95% confidence interval, 1.47-4.12; P<0.001).
The diagnosis of PVS is challenging because of nonspecific symptoms and the need for dedicated pulmonary vein imaging. There is no difference in acute success by type of initial intervention; however, stenting significantly reduces the risk of subsequent pulmonary vein restenosis in comparison with BA.
房颤消融术后肺静脉狭窄(PVS)的发生率虽有所下降,但仍是一种高度致病变异。尽管已有描述肺静脉扩张和支架置入等治疗策略,但这些干预措施的长期影响尚不清楚。我们评估了严重 PVS 的表现,并检查了单独使用球囊血管成形术(BA)或 BA 加支架置入治疗后的再狭窄风险。
这是一项前瞻性、观察性研究,纳入了 2000 年至 2014 年间 124 例经计算机断层扫描诊断为严重 PVS 的患者。
124 例患者的 219 条静脉均通过计算机断层扫描确诊为严重 PVS。102 例(82%)患者在诊断时出现症状。最常见的症状是呼吸困难(67%)、咳嗽(45%)、疲劳(45%)和运动耐量下降(45%)。27%的患者出现咯血。92 条静脉接受了 BA 治疗,86 条静脉接受了支架置入治疗,41 条静脉未接受治疗。观察到 94%的急性手术成功率,且该成功率与初始管理方式无关。113 例接受有创评估的患者中有 4 例(3.5%)发生主要手术并发症,15 例(13.3%)发生轻微并发症。总体而言,42%的静脉发生再狭窄,其中接受支架置入治疗的静脉中有 27%(23 条)和接受 BA 治疗的静脉中有 57%(52 条)发生再狭窄。3 年总的再狭窄率为 37%,BA 治疗的静脉中有 49%和支架置入的静脉中有 25%发生再狭窄(风险比,2.77;95%置信区间,1.72-4.45;P<0.001)。在校正年龄、CHA2DS2-VASc 评分、高血压和研究时间段后,BA 与支架置入相比,再狭窄风险仍存在显著差异(风险比,2.46;95%置信区间,1.47-4.12;P<0.001)。
由于非特异性症状和对专用肺静脉成像的需求,PVS 的诊断具有挑战性。初始干预类型对急性成功率无影响,但与 BA 相比,支架置入可显著降低肺静脉再狭窄的风险。